genXone Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
genXone's earnings have been declining at an average annual rate of -1.1%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 17.2% per year.
Key information
-1.1%
Earnings growth rate
-16.5%
EPS growth rate
| Biotechs Industry Growth | 56.3% |
| Revenue growth rate | 17.2% |
| Return on equity | -24.8% |
| Net Margin | -155.3% |
| Next Earnings Update | 13 May 2024 |
Revenue & Expenses BreakdownBeta
How genXone makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -4 | 3 | 0 |
| 30 Sep 23 | 3 | -4 | 4 | 0 |
| 30 Jun 23 | 3 | -3 | 4 | 0 |
| 31 Mar 23 | 4 | -2 | 4 | 0 |
| 31 Dec 22 | 11 | 0 | 4 | 0 |
| 30 Sep 22 | 18 | 5 | 4 | 0 |
| 30 Jun 22 | 21 | 6 | 4 | 0 |
| 31 Mar 22 | 25 | 9 | 4 | 0 |
| 31 Dec 21 | 23 | 9 | 3 | 0 |
| 30 Sep 21 | 25 | 9 | 4 | 0 |
| 30 Jun 21 | 27 | 9 | 3 | 0 |
| 31 Mar 21 | 23 | 8 | 3 | 0 |
| 31 Dec 20 | 20 | 7 | 2 | 0 |
| 30 Sep 20 | 10 | 3 | 1 | 0 |
| 30 Jun 20 | 6 | 1 | 1 | 0 |
| 31 Mar 20 | 3 | 0 | 1 | 0 |
| 31 Dec 19 | 0 | -1 | 1 | 0 |
| 30 Sep 19 | 0 | -1 | 1 | 0 |
| 30 Jun 19 | 0 | -1 | 1 | 0 |
| 31 Mar 19 | 0 | -1 | 1 | 0 |
| 31 Dec 18 | 0 | -1 | 0 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
Quality Earnings: GX1 is currently unprofitable.
Growing Profit Margin: GX1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GX1 is unprofitable, and losses have increased over the past 5 years at a rate of 1.1% per year.
Accelerating Growth: Unable to compare GX1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GX1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: GX1 has a negative Return on Equity (-24.84%), as it is currently unprofitable.